A study of 185,066 people with type 2 diabetes found that those taking a GLP-1 receptor agonist had a slightly higher risk of developing diabetic retinopathy but a lower likelihood of serious complications such as vision loss ( JAMA Network Open , Aug
Clinical evidence does not consistently demonstrate superiority of either form in correcting deficiency or improving symptoms such as fatigue or neuropathy
Sometimes, despite doing everything right, a patient just doesnt respond the way wed hope, she says
While this one may seem obvious, it always bears repeating
Understanding your legal rights regarding drug testing and prescription medications can further protect you from potential issues
Available here Journal of the International Society of Sports Nutrition: Metabolic adaptation to weight loss: implications for the athlete. February 27, 2014